We have discovered a single tumour factor which causes cancer cachexia, a wasting condition that is one of the worst complications of malignancy, for which there is no current effective treatment. We have developed antibodies which effectively block this condition in preclinical models and have produced human/humanised version of this. This application is to characterise these human antibodies to allow us proceed to clinical trials.
Alpha-particles linked to recombinant antibodies targeting tumour cells have potential to effectively treat tumours while minimising normal tissue side effects. We will explore a novel alpha-particle therapy approach to solid tumours, by delivering 225Ac directly into tumour cells, or into cells that support the tumour (microenvironment). This approach will hopefully result in development of a new approach to treatment of cancers that are resistant to conventional therapies.
Melanotransferrin: A “Missing Link” And A Novel Pharmacological Target For Treatment
Funder
National Health and Medical Research Council
Funding Amount
$613,848.00
Summary
Despite >30 years of research, the precise function of the protein, melanotransferrin (MTf), is unknown. However, we have breakthrough evidence that MTf stimulates WNT signalling as a major driver in cancer progression. We will investigate this hypothesis, which will underpin new cancer therapies. Indeed, we designed a new class of drugs that target the WNT pathway via up-regulating the WNT inhibitor, NDRG1. This drug (DpC) inhibits MTf expression to block tumour cell growth and metastasis.
Tailoring superconducting hybrid multilayered film systems for electric and electronic applications. This project focuses on the development of new scientific and technological aspects of the fabrication, properties and operation of novel hybrid systems for revolutionizing electricity handling and electronics. It will also solve some existing problems of film structures with promising multilayer technology. Hybrid systems, often make the headlines in science and are gaining an increasingly promi ....Tailoring superconducting hybrid multilayered film systems for electric and electronic applications. This project focuses on the development of new scientific and technological aspects of the fabrication, properties and operation of novel hybrid systems for revolutionizing electricity handling and electronics. It will also solve some existing problems of film structures with promising multilayer technology. Hybrid systems, often make the headlines in science and are gaining an increasingly promising outlook in materials engineering, nanotechnology and electronics, promising eventual application in a broad range of industries. This project will establish Australia's capability at the forefront in this area. The outcomes predicted will benefit existing Australian companies and may establish new companies dealing with these hybrid systems.Read moreRead less
Humanisation And Pre-clinical Validation Of A Therapeutic Anti-cancer Antibody
Funder
National Health and Medical Research Council
Funding Amount
$699,136.00
Summary
This grant will develop a novel antibody against a protease expressed on cancer cells. Preclinical studies, and antibody humanisation, will be performed. This project will also provide vital information on optimal therapeutic approaches with the antibody that can be ultimately taken into human trials.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE120100006
Funder
Australian Research Council
Funding Amount
$600,000.00
Summary
An adaptable and dedicated linear accelerator for medical radiation research. Leading radiation scientists developing innovative methods and devices for treating cancer patients will collaborate in future research using this highly adaptable linear accelerator for medical radiation research. Innovations in tumour targeting, better patient safety, new medical devices and improved cancer outcomes are expected.
ADAM Metalloprotease Inhibition For Treatment Of Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$770,925.00
Summary
Colorectal cancer (CRC) causes over 4000 deaths/year, typically from developing drug resistance and spreading to other organs (metastasis). These processes involve tumour cells called cancer stem cells (CSCs), which rely on specific cell surface proteins for survival and function. We are developing antibodies against one of these type of proteins, to test in mouse models of CRC. These already show promise in targeting CSCs and inhibiting drug-resistance and metastasis in mice.
Linkage Infrastructure, Equipment And Facilities - Grant ID: LE0668302
Funder
Australian Research Council
Funding Amount
$210,000.00
Summary
Floating-zone Crystal Growth Facility. Optical floating-zone furnaces are powerful and efficient tools for the discovery and characterisation of new materials. They are widely used in the solid-state chemistry, condensed-matter physics, materials science, and engineering communities. This optical floating-zone furnace, the first in Australia, will support and encourage the growing number of local researchers in these fields. It will allow them to take much better advantage of the new research re ....Floating-zone Crystal Growth Facility. Optical floating-zone furnaces are powerful and efficient tools for the discovery and characterisation of new materials. They are widely used in the solid-state chemistry, condensed-matter physics, materials science, and engineering communities. This optical floating-zone furnace, the first in Australia, will support and encourage the growing number of local researchers in these fields. It will allow them to take much better advantage of the new research reactor and synchrotron being constructed in Australia by maximising their ability to grow crystals of technologically and scientifically important materials, particularly electronic and magnetic materials, for fundamental and applied research at those facilities.Read moreRead less